

Supplementary Materials:

In vitro patient-derived 3D mesothelioma tumor organoids facilitate patient-centric therapeutic screening

Andrea R. Mazzocchi^{1,2†}, Shiny A. P. Rajan^{1,2†}, Konstantinos I. Votanopoulos^{3,4,*}, Adam R. Hall^{1,2,4,*}, and Aleksander Skardal^{1,2,4,5,*}

¹Wake Forest Institute for Regenerative Medicine, Wake Forest School of Medicine, Medical Center, Winston-Salem, NC, 27101, USA.

²Virginia Tech-Wake Forest School of Biomedical Engineering and Sciences, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157, USA.

³Department of Surgery-Surgical Oncology, Wake Forest Baptist Medical Center, Medical Center Boulevard, Winston-Salem, NC, 27157, USA.

⁴Comprehensive Cancer Center at Wake Forest Baptist Medical, Medical Center Boulevard, Winston-Salem, NC, 27157, USA.


⁵Department of Cancer Biology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC, 27157, USA.

†These authors contributed equally to this work


*Correspondence authors, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157

E-mail addresses: askardal@wakehealth.edu (A. Skardal); arhall@wakehealth.edu (A. R. Hall); kvotanop@wakehealth.edu (K. I. Votanopoulos)

Supplementary Figures



Supplementary Figure 1. Subject 1 organoid LIVE/DEAD segmentation. Same data as in Fig. 3a of the main text, but with segmented images resulting from Imaris analysis software, showing live (green) and dead (red) cell positions.



Supplementary Figure 2. Subject 2 organoid LIVE/DEAD segmentation. Same data as in Fig. 3c of the main text, but with segmented images resulting from Imaris analysis software, showing live (green) and dead (red) cell positions.